[Therapeutic strategy for CIDP (chronic inflammatory demyelinating polyneuropathy)]

Area of Science:

• Neurology
• Immunology

Context:

• Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder affecting peripheral nerves.
• Current first-line therapies (FLTs) include corticosteroids, intravenous immunoglobulin (IVIg), and plasmapheresis, but head-to-head comparisons are lacking.

Purpose:

• To review the current landscape of FLTs for CIDP, discuss the limitations of complementary therapies, and highlight areas for future research.
• To provide guidance on selecting appropriate FLTs and emphasize diagnostic re-evaluation for non-responsive cases.

Summary:

• No single first-line therapy (corticosteroids, IVIg, plasmapheresis) is proven superior for specific CIDP phenotypes.
• The efficacy of complementary therapies like immunosuppressants is not supported by robust clinical trials, precluding their use as second-line treatments.
• Recent updates include IVIg for maintenance therapy and the comparable effectiveness of pulsed dexamethasone versus continuous prednisolone. IVIg offers faster onset, while methylprednisolone may reduce relapses post-treatment.
• Diagnostic re-evaluation is recommended for patients unresponsive to all FLTs before initiating complementary therapies.

Impact:

• This review underscores the need for comparative studies to optimize CIDP treatment selection based on individual patient phenotypes.
• It clarifies the current evidence-based approach to CIDP management, discouraging the use of unproven complementary therapies.
• Identifies critical knowledge gaps, advocating for further research into FLT combinations, such as IVIg and corticosteroids, for CIDP induction therapy.